| |
AS03C
|
AS03C-MPL25
|
AS03C-MPL50
|
AS03B
|
AS03B-MPL25
|
AS03B-MPL50
|
AS03A
|
AS03A-MPL25
|
Non-adjuvanted ≥65 y
|
Non-adjuvanted 18–40 y
|
|---|
| |
N=204
|
N=202
|
N=198
|
N=202
|
N=199
|
N=199
|
N=202
|
N=198
|
N=200
|
N=203
|
|
Day 0–21
|
0 (0.0%)
|
2 (1.0%)
|
2 (1.0%)
|
3 (1.5%)
|
2 (1.0%)
|
4 (2.0%)
|
2 (1.0%)
|
4 (2.0%)
|
0 (0.0%)
|
0 (0.0%)
|
|
Day 21–179
|
18 (8.8%)
|
8 (4.0%)
|
16 (8.1%)
|
9 (4.5%)
|
9 (4.5%)
|
19 (9.5%)
|
5 (2.5%)
|
10 (5.1%)
|
15 (7.5%)
|
3 (1.5%)
|
- All participants received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an adjuvant. AS03 is a squalene and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4’- monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).
